KOSDAQFood & Beverage270870

Newtree

₩3,375▼ 1.89%2026-11-18 close
Market Cap
₩30.4B
Turnover
₩45,091,665
Volume
10K
Shares out.
9M
PER
—
PBR
0.3×
EPS
-₩421
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Inner-beauty competition keeps Newtree in the red

Newtree swung to an operating loss in 2025, and its quarterly operating results have since alternated between small profits and losses, so whether sales recovery is translating into stable earnings remains to be confirmed.

  1. 1

    Annual sales declined for three consecutive years from 2023 to 2025, falling to KRW 101.1 billion in 2025 from KRW 198.6 billion in 2022.

  2. 2

    In 2025 Newtree recorded an operating loss of KRW 2.27 billion and a net loss attributable to controlling shareholders of KRW 2.42 billion, which the company linked mainly to intensified inner-beauty competition and higher spending.

  3. 3

    Quarterly sales in 2026 were KRW 25.9 billion, KRW 28.4 billion and KRW 27.2 billion, while operating results alternated between a small loss, a small profit and a loss of KRW 2.36 billion.

  4. 4

    Over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, net losses attributable to controlling shareholders totaled KRW 3.79 billion, while the debt-to-equity ratio stood at 30.0% at the end of 2025, down from 48.5% in 2022.

  5. 5

    The stock trades at a low price-to-book ratio, while the last four quarters of net losses leave the earnings-based multiple uncalculated, so valuation hinges on asset backing and an earnings recovery.

02

Business structure

Newtree develops inner-beauty health functional food ingredients and finished products using natural biotechnology, operating in skin health, diet, superfood and functional food categories through both B2C and B2B channels.

Its flagship brand is Ever Collagen, and the Pandora inner-beauty line also contributes to sales. The company says it develops proprietary ingredients on its NRDO system.

Disclosures do not break out sales by product line, so it is difficult to say quantitatively whether finished products or raw ingredients anchor the business.

In raw materials, the company plans to export collagen peptides to advanced markets including Japan, the United States and Europe, and a 2025 press report said it intends to invest KRW 10 billion through 2028 to secure 12 new ingredients.

Overseas finished-product sales center on Ever Collagen through listings on Amazon in the United States and Qoo10 in Japan, with Malaysia also being pursued. In distribution, home shopping sales have shrunk while the company aims to widen market share through online channels built on its brand equity.

The portfolio is expanding into new categories such as omega-3 and the superfood lupinine, and a plant-based omega-3 product was added under the Dr.UN total healthcare brand. On competition, intensifying competition in the inner-beauty market and shifting consumer trends have been cited as reasons for falling sales.

In the nine months through the third quarter of 2025, weak sales of the core product lines fed into the earnings decline, which reads as a structural weakness.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩25.4B₩500M2.0%
2025Q4₩24.5B-₩3.8B−15.4%
2026Q1₩25.9B-₩26,131,908−0.1%
2026Q2₩28.4B₩6,969,9490.0%
2026Q3₩27.2B-₩2.4B−8.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩198.6B₩4.5B₩4.7B2.3%4.9%48.5%
2023₩151.4B₩10.5B₩4.6B7.0%4.6%31.0%
2024₩122B₩4.9B₩4.8B4.0%4.5%28.8%
2025₩101.1B-₩2.3B-₩2.4B−2.2%−2.3%30.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual sales fell from KRW 198.6 billion in 2022 to KRW 151.4 billion in 2023, a 23.8% decline, then to KRW 122 billion in 2024, down 19.4%, and to KRW 101.1 billion in 2025, down 17.1%.

The decline has run for three consecutive years from 2023 through 2025, with 2022 the largest year and 2025 the smallest in the 2022 to 2025 span.

Operating profit rose from KRW 4.54 billion in 2022 to KRW 10.5 billion in 2023, a 131.8% increase, then fell to KRW 4.93 billion in 2024, down 53.1%, and turned into an operating loss of KRW 2.27 billion in 2025. Operating margin moved from 2.3% in 2022 to 7.0% in 2023, 4.0% in 2024 and -2.2% in 2025.

Net profit attributable to controlling shareholders held at KRW 4.74 billion in 2022, KRW 4.61 billion in 2023 and KRW 4.81 billion in 2024 before turning into a net loss of KRW 2.42 billion in 2025.

Net profit including non-controlling interests, at a net loss of KRW 2.56 billion in 2025, is a separate figure and should be read apart from the controlling-shareholder line.

The company attributed the 2025 swing to intensified competition in the inner-beauty market that reduced sales, higher clinical, new-product and marketing spending to reshape its brand portfolio, higher development and marketing costs for new businesses and overseas expansion, and a temporary valuation loss at an investee.

Operating cash flow improved from negative KRW 3.63 billion in 2022 to KRW 11.2 billion in 2025, the largest of the four years. At the end of 2025, total equity stood at KRW 105.1 billion, equity attributable to controlling shareholders at KRW 103.8 billion, and total liabilities at KRW 31.6 billion.

Quarterly results moved from an operating profit of KRW 514 million and controlling-shareholder net profit of KRW 1.19 billion in the third quarter of 2025, to an operating loss of KRW 3.78 billion and a controlling-shareholder net loss of KRW 4.34 billion in the fourth quarter.

In 2026, the first quarter showed an operating loss of KRW 26.13 million, the second an operating profit of KRW 6.97 million, and the third an operating loss of KRW 2.36 billion, while sales were KRW 25.9 billion, KRW 28.4 billion and KRW 27.2 billion, with the third quarter up 7.0% year on year.

The second-quarter controlling-shareholder net profit of KRW 7.74 billion was far larger than its operating profit, so the gap between operating and non-operating items is a point to examine in the next periodic report.

05

Industry analysis

Newtree's end market is inner-beauty and health functional foods. A 2023 research note described the segment as having grown at an average annual rate of 35.6% over 2016 to 2021, but noted that high-growth aftereffects and a broader slowdown in the health functional food industry hit it in 2023.

In its 2025 annual report, the company cited intensifying competition in the inner-beauty market as a direct cause of lower sales. Sales channels are also shifting, with home shopping losing weight relative to online retail and overseas online platforms.

Brand strength and ingredient development capability are the key variables in health functional foods. Newtree emphasizes proprietary ingredient development and a focus on its core brand, but in 2025 marketing costs rose relative to sales as more competing products entered the market.

Within the food and beverage sector, Newtree is a small to mid-sized health functional food company with a high share of finished-product sales and heavy reliance on a single brand, unlike large food groups with diversified portfolios.

Recovery in market share will depend on the efficiency of online channels and the speed at which new ingredients reach commercial use. Its position in the sector is likely to shift with the trajectory of earnings and the outcome of the brand portfolio reorganization.

06

Outlook

The company is carrying into 2026 the tasks it cited for the 2025 swing, namely reshaping its brand portfolio and expanding new and overseas businesses.

In raw materials, a 2025 press report described a plan to invest KRW 10 billion through 2028 to secure 12 new ingredients, and any contribution to earnings from this would most likely come after 2027.

For finished products, the company has targeted visible results from overseas sales through Amazon in the United States and Qoo10 in Japan within two to three years. Domestically, the task is to widen market share through online channels and grow newer categories such as omega-3 and lupinine.

In 2026 sales rose year on year while operating results alternated between profit and loss, so the central question is whether incremental sales are now converting into profit. The next checkpoint is the annual operating margin and the composition of fourth-quarter operating results in the 2026 annual report.

Non-operating items and valuation gains or losses at investees, which affect net profit attributable to controlling shareholders, also need to be tracked.

Progress on securing new ingredients and the trend in overseas sales will show up in disclosures and investor relations materials, and these three markers will indicate how far the cost increases cited for 2025 have eased in 2026.

07

Valuation

PER
—
PBR
0.3×
ROE
-3.7%
EPS
-₩421
BPS
₩10,892
Dividend per share
₩0

Newtree's earnings-based multiple cannot be calculated because net losses over the last four quarters leave no positive earnings base, so valuation comparisons currently rest on net assets and sales trends. Price-to-book sits near the bottom of its historical band, which reads as a discount relative to net assets.

Market capitalization is smaller than total equity at the end of 2025, so how the market values the balance sheet is the starting point for any comparison. The dividend yield is below the sector average, which is typical for a company in loss.

On an earnings basis, the profitable years through 2024 contrast with the loss years from 2025, and the comparison base shifts depending on whether earnings recover.

Against its historical price-to-earnings band, there is currently no meaningful multiple, so price-to-book and the size of the equity base become the main reference points for now. The valuation picture could change once the fourth-quarter 2026 results and the earnings structure in the 2026 annual report are confirmed.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Sales recovery through 2026

Quarterly sales reached KRW 25.9 billion in the first quarter of 2026, KRW 28.4 billion in the second and KRW 27.2 billion in the third, with the third quarter up 7.0% year on year. This contrasts with the three-year annual decline through 2025. If the sales base holds, there is room for operating margin to improve.

Balance sheet stability

At the end of 2025 total liabilities were KRW 31.6 billion against total equity of KRW 105.1 billion, a debt-to-equity ratio of 30.0%. That ratio fell from 48.5% in 2022 to 31.0% in 2023 and has stayed around 30% since. Limited financial burden during loss years gives the company room to carry out its restructuring.

Overseas channels and ingredient expansion

Ever Collagen is listed on Amazon in the United States and Qoo10 in Japan, and Malaysia is also a target market. In ingredients, the company has outlined plans to export collagen peptides to advanced markets such as Japan, the United States and Europe. If overseas sales grow in both finished products and ingredients, dependence on domestic channels could fall.

09

Bear factors

Three years of falling sales and a 2025 swing to losses

Annual sales fell for three consecutive years from 2023 to 2025, reaching KRW 101.1 billion in 2025. Operating profit turned into a loss of KRW 2.27 billion in 2025, and net profit attributable to controlling shareholders swung to a loss of KRW 2.42 billion.

The company's explanation of intensifying inner-beauty competition suggests structural pressure that has not yet eased.

Unstable quarterly operating results in 2026

The third quarter of 2026 posted an operating loss of KRW 2.36 billion and a net loss attributable to controlling shareholders of KRW 7.41 billion. Over the last four quarters, controlling-shareholder net losses totaled KRW 3.79 billion.

The second-quarter profit was only KRW 6.97 million at the operating line, and results have kept swinging between profit and loss.

Cost pressure and the expense of channel shifts

In 2025 clinical, new-product and marketing spending rose, and development costs for new and overseas businesses increased as well. While home shopping sales shrink, expanding online channels requires additional spending. If that spending does not return as sales, the recovery in operating margin could take longer.

10

Risk factors

Product concentration

Weak sales in the Ever Collagen and Pandora inner-beauty lines were cited as a direct cause of the 2025 earnings decline. When sales rely on one brand and one product line, shifts in consumer trends can move results sharply. How fast new categories offset declines in existing products is the core of managing this risk.

Investment costs and non-operating items

The plan to invest KRW 10 billion through 2028 to secure new ingredients could weigh on costs. The 2025 net loss also reflected a temporary valuation loss at an investee.

If investment returns are delayed or investee valuations fall, net profit attributable to controlling shareholders could move differently from operating results.

Small-cap liquidity and regulation

With a market capitalization below total equity, Newtree is a small-cap stock, so price volatility can be large and trading liquidity limited. Health functional foods are subject to ingredient approval procedures and advertising and labeling rules. Delays in ingredient approval or tighter labeling rules could push back product launch schedules.

11

What to watch next

  1. End of March 2027 (statutory filing deadline)

    The 2026 annual report will show full-year sales, operating margin and the composition of fourth-quarter operating results. The key question is how the 2025 operating loss of KRW 2.27 billion and the 2026 quarterly pattern add up for the full year.

  2. End of March 2027 (with the annual report)

    The notes will show how non-operating items and investee valuation gains or losses affected net profit attributable to controlling shareholders. The cause of large gaps between operating profit and net profit, as seen in the second quarter of 2026, should become visible here.

  3. Around May 15, 2027 (first-quarter report filing deadline)

    Compare first-quarter 2027 sales and operating results with the first quarter of 2026, which had sales of KRW 25.9 billion and an operating loss of KRW 26.13 million. Whether quarterly results settle into profit is the checkpoint.

  4. Through 2028 (tracked through annual disclosures)

    Track progress on the plan to secure 12 new ingredients and the pace of the KRW 10 billion investment. How much the ingredient business reduces the volatility of finished-product sales will be the medium-term benchmark.

12

Overall view

Newtree's sales fell from KRW 198.6 billion in 2022 to KRW 101.1 billion in 2025, and the company swung into an operating loss and a net loss attributable to controlling shareholders in 2025.

Quarterly sales in 2026 rose year on year, with the third quarter at KRW 27.2 billion, up 7.0%, so the sales base has partly recovered.

Operating results have not stabilized, however, with an operating loss in the first quarter of 2026, a small operating profit of KRW 6.97 million in the second and an operating loss of KRW 2.36 billion in the third.

Controlling-shareholder net losses over the last four quarters total KRW 3.79 billion, and no earnings-based multiple currently forms. The balance sheet has a strength in a debt-to-equity ratio of 30.0% at the end of 2025.

Intensifying competition in inner-beauty, the decline in home shopping and the cost of new investments remain open issues. The next checkpoints are the annual operating margin and non-operating items in the 2026 annual report, and quarterly results for the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. thevc.kr
  2. comp.wisereport.co.kr
  3. comp.fnguide.com
  4. ssl.pstatic.net
  5. edaily.co.kr
  6. digitaltoday.co.kr
  7. pharm.edaily.co.kr
  8. buffettlab.co.kr
  9. m.thinkpool.com
  10. kr.investing.com
  11. jobkorea.co.kr
  12. m.news.nate.com
  13. markets.hankyung.com
  14. investing.com
  15. jobkorea.co.kr
  16. alphasquare.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis